Erratum to: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition (Nature Medicine, (2018), 24, 7, (968-977), 10.1038/s41591-018-0022-x)

Gabrielle S. Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu, Tianxia Li, David Xu, Steven E. Schumacher, Jens Puschhof, James McFarland, Charles Zou, Austin Dulak, Les Henderson, Peng Xu, Emily O’Day, Rachel Rendak, Wei li Liao, Fabiola Cecchi, Todd Hembrough, Sarit SchwartzChristopher Szeto, Anil K. Rustgi, Kwok Kin Wong, J. Alan Diehl, Karin Jensen, Francesco Graziano, Annamaria Ruzzo, Shaunt Fereshetian, Philipp Mertins, Steven A. Carr, Rameen Beroukhim, Kenichi Nakamura, Eiji Oki, Masayuki Watanabe, Hideo Baba, Yu Imamura, Daniel Catenacci, Adam J. Bass

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)

Abstract

In the Supplementary Information originally published with this article, a lane was missing in the β-actin blot in Supplementary Fig. 2. The lane has been added. The error has been corrected in the Supplementary Information associated with this article.

Original languageEnglish
Pages (from-to)1627
Number of pages1
JournalNature medicine
Volume24
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Erratum to: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition (Nature Medicine, (2018), 24, 7, (968-977), 10.1038/s41591-018-0022-x)'. Together they form a unique fingerprint.

Cite this